HOME About Santen News Investor Relations Products Careers  
 

A New Growth Stage

Chapter 4 : A New Growth Stage


Based on the expertise it had accumulated in the prescription ophthalmic market in Japan, Santen began establishing a foothold in overseas markets. Santen now has eleven operational bases in seven countries overseas, including the United States, Germany and Finland.

1993
Santen Inc.

U.S. subsidiary Santen Inc. established

Santen Inc.conducts the R&D, business development and strategic marketing activities in the U.S.

1994
Santen GmbH

Santen GmbH established in Germany

Santen GmbH started sales operations in Germany in 2002 with the launch of the anti-infective ophthalmic Oftaquix (brand name in Japan: Cravit ).

1995
Hyalein
Hyalein

Hyalein, a treatment for corneal disorders, launched in Japan

Hyalein is a unique drug that repairs damage to the corneal epithelium resulting from dry eye syndrome. In the six years since its launch, sales had exceeded 10 billion yen.

Anti-rheumatic drug Azulfidine EN launched in Japan


Beijing Representative Office opened


1996

Nara Research and Development Center and Shiga Plant opened

Nara Research and Development Center
Nara R&D Center

Shiga Plant
Shiga Plant

1997
Santen Oy
Santen Oy

Acquisition of a Finnish ophthalmic pharmaceutical company and the subsequent establishment of Santen Oy

With the establishment of Santen Oy, Santen gained its first overseas production base and made its entry into the Northern and Eastern European markets.

Taiwan Santen Pharmaceutical Co., Ltd. established


1998

Medium-term plan "Hitomi 21" devised


2000
Cravit
Cravit

Anti-infective ophthalmic Cravit launched in Japan

Cravit has become the first-choice treatment for eye infections for its strong anti-infective action and excellent ability to penetrate ophthalmic tissue.

Santen Pharmaceutical Korea, Co., Ltd. and Guangzhou Representative Office established

In June 2000, Santen received a threat regarding tampering with its over-the-counter eye drops. Concerned for the safety of consumers, Santen disclosed the information immediately and withdrew all its over-the-counter products from the market.

2001
Detantol
Detantol

Detantol, a treatment for glaucoma and ocular hypertension, and Livostin, an anti-allergy ophthalmic solution, launched in Japan


Acquisition of the U.S.-based Advanced Vision Science, Inc.

Advanced Vision Science, Inc. is an ophthalmic medical device manufacturer with strong capabilities in the research and development of intraocular lenses.

2002
Dimple Bottle
Dimple Bottle

Introduced the Dimple Bottle


2003

2003-2005 Medium-term Management Plan devised


2005

Shanghai Representative office established

Santen Pharmaceutical(China) Co., Ltd. establishedd


2006

PAPILOCK Mini ophthalmic solution 0.1%, a treatment for vernal keratoconjunctivitis, launched in Japan

2006-2010 Medium-term Management Plan devised


Prev


Back to top
 
For Shareholders and Investors